<DOC>
	<DOCNO>NCT02269852</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity safety Northern hemisphere 2013-2014 seasonal trivalent inactivate influenza vaccine 60 healthy infant age 6-35 month old , 60 healthy adult age 18-60 year old , 60 healthy senior age &gt; 60 year .</brief_summary>
	<brief_title>The Immunogenicity Safety 2013-2014 Seasonal Trivalent Influenza Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>For adult senior : Healthy adult age 1860 year old , healthy senior age &gt; 60 year old ; Without vaccination history seasonal split influenza vaccine recent 3 year No travel plan study period trial ; Be able understand sign inform consent ; Allergic egg product ingredient study vaccine ; Fever , influenza acute illness vaccination day ; Acute stage chronic illness ; Malignant tumor ; Immunodeficiency , include HIV infection ; GuillainBarre syndrome ; Administration live attenuate vaccine within previous 14 day ; Administration subunit inactivate vaccine within previous 7 day ; Planned participate clinical trial drug vaccine study ; Received immunesuppressive treatment within previous month , plan treatment study ; Pregnant , plan pregnancy ; Axillary temperature &gt; 37.0℃ ; Any factor , judgment investigator , unsuitable study ; For infant : Healthy male female age 6 35 month ; Fullterm birth , birth weight 2,500 gram ; Provided birth certification vaccination card Parent legal guardian able understand sign inform consent ; Received seasonal influenza vaccine June 30 , 2012 ; Acute infection within previous week ; Allergy history , allergic ingredient study vaccine , egg ; History serious adverse reaction ( SAR ) vaccine ; Autoimmune disease immune deficiency , administration immunosuppressive therapy , cell toxic therapy , inhale corticosteroid within previous 6 month ; Congenital malformation , developmental disorder serious chronic disease ; Unstable condition asthma administration corticosteroid recent two year ; Coagulation abnormalities disorder ; History/ family history infantile convulsion , epilepsy , cerebropathy , mental disease ; Without spleen ; Severe neurological disease , GuillainBarre syndrome ; Administration blood product investigational drug within previous month ; Administration live attenuate vaccine within previous 14 day ; Administration subunit inactivate vaccine within previous 7 day ; Received treatment allergy within previous 14 day ; ongoing antituberculosis therapy ; Axillary temperature &gt; 37.0℃ immediately vaccination ; factor , judgment investigator , unsuitable study ;</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>seasonal trivalent inactivate influenza vaccine</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>safety</keyword>
	<keyword>cross-reactivity</keyword>
	<keyword>Northern hemisphere 2013-2014 formulation</keyword>
</DOC>